CSPC returned for the anti-tumour therapy developer's series B round having backed its $147m series A early last year.
China-based cancer therapy developer HaiHe Biopharma has closed a RMB1.2bn ($171m) series B round featuring pharmaceutical group CSPC and Legend Capital, a venture capital offshoot of conglomerate Legend Holdings, DealStreetAsia reported today.
The round was led by private equity firm Warburg Pincus and also featured CMB International and CICC Capital, on behalf of financial services firm China Merchants Bank and investment bank China International Capital Corporation.
Chaos Investment, BioTrack Capital, Yingke PE, Atlas Capital, Alan AMC and Jiangsu Ruihua Investment…
